局部晚期宫颈癌同步洛铂化放疗疗效分析  

Effective Analysis of Synchronization Lobaplatin Chemoradiotherapy for Locally Advanced Cervical Cancer

作　　者：鲁亮[1] 刘爱华 张汉群[1] 李勇[1] 李馨[1] 罗旻[1] LU Liang;LIU Ai-hua;ZHANG Han-qun(Department of Gynecologic Oncology, Guizhou Provincial People＇s Hospital, Guiy- ang, Guizhou, 550002, Chin)

机构地区：[1]贵州省人民医院肿瘤科,贵阳550002 [2]贵州护理职业技术学院,贵阳550002

出　　处：《黑龙江医学》2018年第5期391-393,共3页Heilongjiang Medical Journal

基　　金：贵州省卫生计生委科研项目(gzwkj2011-1-054)

摘　　要：目的分析局部晚期宫颈癌同步洛铂化放疗,确定其毒性及抗瘤活性。方法选取IB2~IVA期未行治疗的宫颈癌患者,基于放疗期间每周一次洛铂。结果 46例患者均完成了放疗,平均治疗时间50 d,9例患者因血小板减少或粒细胞减少延迟治疗,无因胃肠道反应延迟化疗,基于体格检查和CT或MRI检查肿瘤完全缓解率达73.9%。结论局部晚期宫颈癌同步洛铂化疗,患者有比较好的耐受性和较好的有效率。Objective To determine the toxicities of concurrent lobaplatin and chemoradiotherapy in the primary treatment of locally advanced cervix cancer and to ascertain the antitumor activity of this regimen. Method Patients with stage IB-1 to IVA untreated primary cervix cancers were eligible. Lobaplatin was administered on a weekly basis with external radiation therapy（ ERT）. Results 46 evaluable patients were enrolled. All patients completed the prescribed course of radiation therapy. The mean treatment time was 50 days. Treatment of 9 cases were delayed for neutropenia or thrombocytopenia or gastrointestinal toxicity. The objective tumor response based on physical exam findings and computed tomography or magnetic resonance investigation measurements was73. 9%. Conclusion Patients with locally advanced cervix cancer can be treated on schedule with concurrent lobaplatin and pelvic radiation therapy. This regimen is well be tolerated and produces excellent response rates.

关 键 词：化放疗 洛铂 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]